Investment Philosophy Evolution and Core Insights - The transition from "cigar butt" strategy to focusing on "quality companies" reflects a self-renewal of value investment theory and adaptation to market conditions and capital scale changes [2][3] - Early "cigar butt" strategy emphasized safety margin and liquidation logic, with investments based on market price being lower than liquidation value, but these companies often lacked growth potential [3][4] - The mid-term shift to "quality companies" highlighted the importance of economic moats and pricing power, exemplified by the acquisition of See's Candies, which contributed over $1.3 billion in profits [5][6] - The later phase of large-scale investment utilized low-cost long-term funds to build investment leverage, with Berkshire's cash reserves reaching $334.2 billion in 2024 [7][8] Core Insights and Investment Implications - The evolution of investment philosophy from "price" to "quality" emphasizes that intrinsic value, such as brand and management, is more decisive than short-term financial data [9] - Risk control involves a dynamic balance of leverage and scale, with a shift away from leveraged investments as capital scales increased [10] - A long-term perspective is crucial, as demonstrated by Buffett's holdings in Coca-Cola and Apple, which underline the importance of holding quality assets for compounding returns [11] Applicable Methods and Cases for A-shares - Core methodology includes selecting companies with economic moats, such as brand premium exemplified by Kweichow Moutai with a gross margin of 91.5% and ROE of 33% [12][17] - Dynamic assessment of safety margins involves evaluating low valuations with high growth potential, as seen in Hengrui Medicine, which has a dynamic PE of approximately 44 times [14] - Long-term holding and contrarian positioning are illustrated by Wuliangye, currently valued at a dynamic PE of about 8.7 times, with strong brand resilience and expected profit growth [15][16] Practical Cases - Kweichow Moutai demonstrates brand monopoly and cash flow strength, with projected revenue of 170.9 billion in 2024, reflecting a year-on-year increase of 15.7% [17][18] - Contemporary leaders in the new energy sector, such as CATL, hold a global market share of 37% in power batteries, with production capacity planned to reach 670 GWh in 2024 [19][20] - Longi Green Energy, a leader in photovoltaic technology, is expected to benefit from efficiency breakthroughs in HJT battery production [20] Conclusion - The evolution of Buffett's investment approach signifies a shift from "valuation arbitrage" to "value creation," emphasizing the focus on economic moats and dynamic valuation assessments [21] - The insights gained can guide A-share investors to select targets in consumption, healthcare, and new energy sectors, aiming for "reasonable price entry and long-term holding" to achieve compounding growth [21]

JohnV.Oyler（欧雷强） ，1968年出生，百济神州联合创始人，自2010年起一直担任公司执行董事、董事会 主席兼首席执行官。于1990年获得麻省理工学院的理学学士学位，于1996年获得斯坦福大学的工商管理硕 士学位。欧雷强以管理顾问职务在麦肯锡公司（McKinsey&Company）开始其职业生涯。1997年至1998 年，欧雷强担任GentaIncorporated联席首席执行官，该公司为一家在纳斯达克交易所上市的以肿瘤为重点的 生物制药企业。1998年至2002年，欧雷强创立Telephia,Inc.并担任总裁，该公司于2007年被尼尔森公司 （The Nielsen Company）收购。2002年至2004年，欧雷强担任Galenea Corp的首席执行官，该公司为一家致 力于开发新的中枢神经系统疾病治疗方法的生物制药企业。2005年至2009年，欧雷强担任BioDuro,LLC的总 裁兼首席执行官，该公司为一家药品开发外包公司，后被Pharmaceutical Product Development Inc.收购。 2019年，欧雷强正式入选生物技术产业协会（BIO）董事会及其卫生部门理事 ...

Group 1 - Hillhouse Capital has reduced its stake in BeiGene, selling 16 million shares, bringing its total holdings down to 68.55 million shares, which is 4.89% of the company, no longer making it a major shareholder [1] - The sale occurred on May 9, 2025, at a minimum price of $230.23 per share, resulting in proceeds of approximately $3.68 billion [1] - The stock prices of BeiGene across A-shares, H-shares, and U.S. shares have rebounded this year, with U.S. shares seeing an increase of over 30% [1] Group 2 - Following the reduction of its stake in BeiGene, Hillhouse Capital is set to subscribe to the IPO of Hengrui Medicine [3] - Hengrui Medicine plans to issue 225 million H-shares, with a price range of HKD 41.45 to HKD 44.05 per share, potentially raising up to HKD 13.08 billion [3][4] - The IPO is expected to attract significant interest from international investment institutions, including Hillhouse Capital and others [3] Group 3 - Hengrui Medicine's IPO pricing represents a discount of 19.3% compared to the average A-share price over the past ten days [4] - The company aims for a stable pricing strategy to build investor confidence and ensure successful fundraising, avoiding significant post-listing price volatility [5] - Hengrui Medicine and BeiGene are in a competitive race for the title of "Pharmaceutical King" in the A-share market, with Hengrui currently leading by a market cap of 24 billion yuan as of May 15 [5]

Core Viewpoint - CICC maintains the profit forecast for BeiGene (688235.SH, 06160, ONC.US) for 2025 and 2026, keeping the "outperform" rating, with target prices of 280 CNY, 198 HKD, and 332 USD based on DCF model, indicating upside potential of 15.0%, 41.0%, and 43.1% respectively [1] Group 1 - The company's 1Q25 revenue met expectations, reporting 1.117 billion USD, a 49% year-on-year increase, with product revenue at 1.109 billion USD, up 48%, and a GAAP net profit of 1.27 million USD, exceeding expectations due to revenue growth outpacing operating expenses [2] - Sales of Zanubrutinib reached 792 million USD in 1Q25, a 62% year-on-year increase, accounting for 71.4% of product revenue, with US sales at 563 million USD, up 60%, driven by increased demand, particularly in CLL indications [3] - The company achieved its first quarterly profit turnaround, maintaining guidance for 2025 with expected revenue of 4.9 to 5.3 billion USD, a year-on-year growth of 29% to 39%, and GAAP operating expenses of 4.1 to 4.4 billion USD, projecting a positive GAAP operating profit for 2025 [4] Group 2 - The company has several highlights for 2025-2026, including the approval of BCL2 for R/R CLL treatment, with phase II clinical data expected in 2H25, and plans for a global accelerated filing; ongoing phase II trials for BTK CDAC in r/r CLL with data expected in 2026, and a head-to-head trial with Eli Lilly's Pirto starting in 2025 [5] - In the solid tumor field, preliminary data for CDK4i, CDK2i, and B7H4 ADC is expected in 1H25, with PoC validation for several products planned for 2H25, including collaborations with Amgen on Tarlatamab, which recently met primary clinical endpoints in a phase III trial for 2L SCLC [5]

Group 1: Institutional Research Trends - Since May, 317 A-share listed companies have been investigated by institutions, with a focus on mechanical equipment and medical biology sectors [1] - BeiGene, Ltd. received the highest number of institutional visits at 256, followed by Shenzhen Santech Circuit Co., Ltd. and Fujian Hengda New Materials Co., Ltd. [1] - Institutions are concentrating their research on key technology areas, particularly in emerging technology industry chains, from foundational hardware support to terminal application expansion [1] Group 2: Pharmaceutical Industry Insights - The pharmaceutical and biotechnology sectors are seeing a focus on innovation breakthroughs and international expansion, with BeiGene reporting strong growth in its European business and increasing market share [1] - BeiGene's drug, BeiZaiAn®, has successfully launched in Germany and Austria, with reimbursement expanding in multiple countries [1] Group 3: Traditional Chinese Medicine Performance - Traditional Chinese medicine companies, such as Guangyuyuan Traditional Chinese Medicine Co., Ltd., reported significant growth in Q1, with revenue and net profit increasing by 21.48% and 53.94% respectively [2] - The Chinese innovative drug sector is entering a phase of realization, with expectations for continued investment opportunities through 2025 [2] Group 4: Emerging Technology Companies - Companies involved in AI, humanoid robots, and low-altitude economy sectors are becoming focal points for institutional research [2] - Xiangxin Technology Co., Ltd. has received 170 institutional visits since May, focusing on precision stamping molds and metal structural components [2] Group 5: Future Growth Projections - Shenzhen Rease Intelligent Control Co., Ltd. aims for a revenue growth of 20% to 30% year-on-year by 2025, focusing on motion control markets [3] - Shenzhen Santech Circuit Co., Ltd. is benefiting from the increasing demand for high-performance PCB products driven by advancements in AI technology [3] - Institutions are signaling investment opportunities in innovative drugs, AI, and humanoid robots, indicating strong growth potential in these sectors [3]

Core Viewpoint - The executive order titled "Providing 'Most Favored Nation' Pricing for Prescription Drugs for American Patients" aims to align U.S. drug prices with those of other developed countries, potentially disrupting the U.S. pharmaceutical market and impacting innovation drug commercialization [2][6][11]. Summary by Sections Executive Order Overview - The executive order mandates the implementation of a "Most Favored Nation" pricing system, allowing U.S. patients to access drug prices equal to or lower than those in other developed nations [2][6]. - It encourages pharmaceutical companies to bypass intermediaries and sell directly to consumers at these prices, while also considering the import of lower-priced drugs from other countries [2][6]. Impact on Medicare and Medicaid - The order primarily affects Medicare and Medicaid, which together account for approximately 40% of U.S. healthcare payments, while commercial insurance covers over 40% [2][3]. - The direct impact on innovative drugs is expected to be limited in the short term, as these are mainly covered by commercial insurance, which the order does not directly influence [3][11]. Market Dynamics and Pharmaceutical Strategies - The order could lead to a shift in how pharmaceutical companies approach market rights, with a potential focus on retaining global rights rather than just overseas rights to control drug development and pricing [4][11]. - There is concern that if the order is implemented, some new drugs may only be launched in the U.S., delaying or preventing their availability in other regions [4][11]. Financial Implications - The U.S. accounts for about 75% of global pharmaceutical profits, and the order aims to address the imbalance where American consumers subsidize lower prices in other countries [6][7]. - The executive order states that Americans should not pay significantly higher prices for identical drugs produced in the same facilities [6][7]. Innovation Drug Market Outlook - The executive order may lead to a decrease in investment in U.S. innovation drugs, potentially increasing reliance on Chinese drug development [11]. - The high payment capacity of the U.S. market, which has historically supported high drug prices, may be challenged, affecting the dynamics of global drug pricing and availability [11]. Case Study: Zebutine - Zebutine, a BTK inhibitor, has seen significant sales growth, with global sales exceeding $4.7 billion and projected U.S. sales of $2 billion in 2024 [10]. - The drug's pricing strategy in the U.S. aligns with that of its competitors, but the potential changes in pricing dynamics could impact future pricing strategies and market access [10][11].

Core Viewpoint - The article discusses the implications of President Trump's executive order on drug pricing, which aims to implement a "Most Favored Nation" pricing system for prescription drugs in the U.S., aligning prices with those in other developed countries [2][5][6]. Group 1: Executive Order Details - The executive order mandates that U.S. patients receive drug prices equal to or lower than those in other developed countries, encouraging pharmaceutical companies to sell directly to consumers and consider importing lower-priced drugs [2][5]. - The order specifically impacts Medicare and Medicaid, which together account for approximately 40% of U.S. healthcare payments, while commercial insurance, which covers over 40%, remains unaffected [2][3]. Group 2: Industry Reactions and Implications - Industry experts believe that the immediate impact on innovative drugs will be limited, as commercial insurance primarily covers these drugs, and Medicare and Medicaid mainly deal with generic and off-patent medications [3][7]. - The executive order is seen as a political move to fulfill campaign promises rather than a concrete plan, with skepticism about its actual implementation and effectiveness [3][7]. Group 3: Market Dynamics - The U.S. pharmaceutical market, which accounts for 70% of global innovative drug sales, may see a shift in how companies approach market rights, potentially leading to a focus on U.S. market exclusivity at the expense of other regions [4][9]. - The article highlights that U.S. consumers currently pay three times more for brand-name drugs compared to the average prices in OECD countries, indicating a significant pricing disparity that the order aims to address [5][6]. Group 4: Case Study - Zymeworks - Zymeworks' BTK inhibitor, Zebutine, serves as a case study, having achieved over $4.7 billion in global sales since its U.S. approval in 2019, with a significant portion of revenue derived from the U.S. market [8]. - The high pricing strategy in the U.S. has been supported by the market's willingness to pay, but this dynamic may change if the "Most Favored Nation" pricing is implemented [9].

A 股代码：688235 A 股简称：百济神州 公告编号：2025-023 关于股东权益变动的提示性公告 投资者 HHLR Fund, L.P.及其联属实体保证向本公司提供的信息真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息 一致。 一、 信息披露义务人的基本信息 1.身份类别 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | | ☑其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 重要内容提示： 权益变动方向 比例增加□ 比例减少☑ 权益变动前合计比例 6.03% 权益变动后合计比例 4.89% 本次变动是否违反已作出的承 诺、意向、计划 是□ 否☑ 是否触发强制要约收购义务 是□ 否☑ | 信息披露义务人名称 | | | 投资者身份 ...

Core Viewpoint - HHLR Fund, L.P. has reduced its stake in BeiGene to 4.89% after selling 16 million shares, no longer being a major shareholder [1] Group 1 - HHLR Fund, L.P. and its affiliates sold 16 million shares of BeiGene on May 9, 2025 [1] - The total number of shares held by HHLR Fund, L.P. decreased to 68.55 million shares [1] - The ownership percentage of HHLR Fund, L.P. changed from 6.03% to 4.89% [1]

Group 1 - The company plans to change its registered location from the Cayman Islands to Switzerland by continuing its registration as a joint-stock company in Switzerland and canceling its registration in the Cayman Islands [1][2] - On May 13, 2025, the company's board of directors unanimously resolved to issue 133,000,000 shares to BG NC 2, Ltd., a wholly-owned subsidiary registered in the Cayman Islands, under the previously approved stock incentive plan [1][2] - The new shares will be held by BGNC2 for the benefit of incentive recipients and are intended to fulfill the company's obligations under the 2016 option and incentive plan [3] Group 2 - The issuance of new shares is within the authorized limit of the previously approved stock incentive plan and does not require further approval from the company's shareholders [2] - The new shares will be created, issued, and subscribed before the completion of the proposed continuation registration, exempting them from Swiss issuance stamp tax and withholding tax [3] - The company will fulfill its information disclosure obligations based on the progress of related matters, and investors are advised to pay attention to investment risks [3]